FDA Issues Setback to Rocket Pharmaceuticals’ Gene Therapy for Rare Pediatric Disease
In a setback for Rocket Pharmaceuticals, the FDA has issued a Complete Response Letter rejecting its gene therapy, Kresladi, designed to treat severe leukocyte adhesion deficiency-I (LAD-I). The agency’s decision comes with a request for additional chemistry, manufacturing, and controls (CMC) information to complete their review process. Initially slated for a March 2024 decision, Kresladi’s … Read more